Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis

Andrew Spencer, MBBS, FRACP, FRCPA, DM, Peter Mollee, MBBS, MMSc, FRACP, FRCPA, Hilary Anne Blacklock, FRACP, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, P. Joy Ho, MBBS DPhil FRACP FRCPA, Ruth Spearing, MD, Jay Hocking, MBBS, FRACP, FRCPA, Bradley Augustson, MBBS FRACP FRCPA, H. Miles Prince, MBBS (Hons), MD FRACP, FRCPA, AFRCMA, MACD, Elizabeth M. Moore, PhD, Zoe McQuilten, Erica M. Wood, MBBS, FRACP, FRCPA, Cameron Wellard

Blood (2019) 134 (Supplement_1): 269.

https://doi.org/10.1182/blood-2019-129431

Published: 2019

Journal Articles

Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose Dexamethasone

Anna Kalff, MBBS, Tiffany Khong, BSc, PhD, Malarmathy Ramachandran, Sam Norton, PhD, Andrew Mitchell, PhD, John Reynolds, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Noemi Horvath, MBBS FRACP FRCPA, Peter Mollee, MBBS, MMSc, FRACP, FRCPA, Nola Kennedy, Roslyn Kemp, Andrew Spencer, DM

Blood (2019) 134 (Supplement_1): 3186.

https://doi.org/10.1182/blood-2019-130154

Published: 2019

Journal Articles

High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?

Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Joel Wight, MBBS, Kathryn Jackson, MBBS, Ashanka Mahilal Beligaswatte, BA, MBBS, MD FRACP, FRCPA, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Glen Kennedy, MBBS, FRACP, FRCPA, Louisa Martin, MBBS, Ian D. Lewis, MBBS PhD FRACP FRCPA, Devendra Hiwase, MBBS, FRACP, FRCPA, MD PhD, Daniela Zantomio, FRACP, FRCPA, MBBS, Simon Z. He, MBBS,FRACP,FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Kirk Morris, FRACP FRCPA MBBS, Peter Mollee, MBBS, MMedSc, FRACP, FRCPA, Paula Marlton, MBBS

Blood (2016) 128 (22): 3989.

https://doi.org/10.1182/blood.V128.22.3989.3989

Published: 2016

Journal Articles

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Blood (2016) 128 (22): 646.

https://doi.org/10.1182/blood.V128.22.646.646

Published: 2016

Journal Articles

Clinical Relevance of Partial Response in the Marrow (PRm) after Failure of Frontline Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML)

Shaun Fleming, MBBS (Hons), FRACP, FRCPA, Doen Ming Ong, MBBS, Kathryn Jackson, MBBS, FRACP, FRCPA, Sharon Avery, MBBS (Hons), FRACP, FRCPA, Peter Mollee, MBBS, MMedSc, FRACP, FRCPA, Paula Marlton, MBBS, FRACP, FRCPA, Glen A Kennedy, MBBS, FRACP, FRCPA, Andrew Wei, MBBS, FRACP, FRCPA, PhD

Blood (2015) 126 (23): 2512.

https://doi.org/10.1182/blood.V126.23.2512.2512

Published: 2015

Journal Articles

Emergence of Fc-Gamma-Riib-Dominance Contributes to Resistance to Therapeutic Antibodies in Patients with Chronic Lymphocytic Leukaemia

Melinda Burgess, Sally Mapp, MBBS, PhD FRACP, FRCPA, Roberta Mazzieri, PhD, Jonathan Ellis, BSc, MSc, PhD, Catherine Cheung, Lynne Chambers, Stephen Mattarollo, BSc, PhD, Peter Mollee, MBBS, MMedSc, FRACP, FRCPA, Devinder Gill, MB FRCPath FRACP FRCPA, Nicholas Saunders, BSc, PhD

Blood (2015) 126 (23): 447.

https://doi.org/10.1182/blood.V126.23.447.447

Published: 2015

Journal Articles

Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients

Blood (2015) 126 (23): 816.

https://doi.org/10.1182/blood.V126.23.816.816

Published: 2015

Journal Articles

Diagnosis of Amyloidosis Subtype By Laser-Capture Microdissection (LCM) and Tandem Mass Spectrometry (MS/MS) Proteomic Analysis

Peter Mollee, MBBS, MMedSc, FRACP, FRCPA, Patricia Renaut, MBBS, FRCPA, Samuel Boros, MBBS, FRCPA, Dorothy Loo, MSc, Michelle Hill, PhD BSc (Hon), BA

Blood (2015) 126 (23): 1779.

https://doi.org/10.1182/blood.V126.23.1779.1779

Published: 2015

Journal Articles

Clinical Comparison of the Freelite and N-Latex Serum Free Light Chain (FLC) Assays in the Diagnosis and Monitoring of AL Amyloidosis

Sally Mapp, MBBS, FRACP, FRCPA, Jill Tate, BSc, MSc, FFSc, Carel Pretorius, MBChB, FCPathChem(SA), Peter Mollee, MBBS, FRCPA, FRACP, MMSc

Blood (2012) 120 (21): 4991.

https://doi.org/10.1182/blood.V120.21.4991.4991

Published: 2012

Journal Articles

A Phase II Study of Risk-Adapted Intravenous Melphalan in Patients with AL Amyloidosis,

Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Campbell Tiley, MBBS, FRACP, FRCPA, Ilona Cunningham, John Moore, Miles Prince, MD, FRACP, FRCPA, Paul Cannell, MBBS, FRCPA, FRACP, Steve Gibbons, FRCPA, FRACP, MB, CHB, Jill Tate, BSc, MSc, FFSc, Sanjoy Paul, PhD, MSc, Devinder S Gill, MD

Blood (2011) 118 (21): 3973.

https://doi.org/10.1182/blood.V118.21.3973.3973

Published: 2011

Journal Articles

Sequential Treatment with Rituximab Followed by CHOP Chemotherapy in Adult B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) - Establishing a New Standard of Care: Final Results From the Prospective International Multicenter PTLD-1 Trial

Ralf Trappe, MD, PhD, Stephan H.K. Oertel, MD, Veronique Leblond, MD, PhD, Peter Mollee, MBBS, MMedSc, Monica Sender, MD, Petra Reinke, MD, PhD, Ruth Neuhaus, MD, Hans Lehmkuhl, MD, PhD, Heinz A. Horst, MD, Gilles Andre Salles, MD, PhD, Franck Morschhauser, Arnaud Jaccard, MD, PhD, Thierry Lamy, MD, PhD, Malte Leithäuser, MD, Ioannis Anagnostopoulos, MD, PhD, Martine Raphael, MD, PhD, Hanno Riess, MD, PhD, Sylvain Choquet, MD

Blood (2011) 118 (21): 878.

https://doi.org/10.1182/blood.V118.21.878.878

Published: 2011

Journal Articles

Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6

Colm Keane, MB BCh BAO MSc MRCPI FRCPath, Linda Shen, FRCPA, Erica Han, Jamie P Nourse, PhD, Rod Lea, PhD, Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Devinder S Gill, MD, Maher K Gandhi, PhD, FRACP, FRCPath, FRCP

Blood (2011) 118 (21): 1585.

https://doi.org/10.1182/blood.V118.21.1585.1585

Published: 2011

Journal Articles

ZAP-70 Expression Measured by Quantitative PCR (QPCR) As a Prognostic Marker in Chronic Lymphocytic Leukaemia (CLL)

Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Raymond H. Banh, MBBS, FRACP, FRCPA, Catherine Cheung, Russell Saal, Lynne Chambers, Tennille Pelly, Devinder S Gill, MD

Blood (2011) 118 (21): 4602.

https://doi.org/10.1182/blood.V118.21.4602.4602

Published: 2011

Journal Articles

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study

Peter T. Tan, MBBS, Kate Reed, BSc, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Othon L Gervasio, DDS, MS, PhD, Ivo J. Winiger, MD, Dirk Hönemann, MD, Andrew H Wei, MBBS, PhD, Andrew Spencer, MD

Blood (2011) 118 (21): 1529.

https://doi.org/10.1182/blood.V118.21.1529.1529

Published: 2011

Journal Articles

WT1 Expression Levels at Diagnosis and as a Marker of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukaemia (AML).

James X Gray, MD, PhD, Lyle McMillen, PhD, Russell Saal, MMedSc, Steven Lane, MBBS, Peter Mollee, MBBS, Robert Bird, MBBS, Devinder Gill, MBChB, Paula Marlton, MBBS

Blood (2009) 114 (22): 2639.

https://doi.org/10.1182/blood.V114.22.2639.2639

Published: 2009

Journal Articles

Treatment of Acute Promyelocytic Leukaemia in Jehovah’s Witness(JW) Population

Colm G Keane, MB, BCH, BAO, MRCPI, Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Paula Marlton, MBBS, FRCPA, FRACP, Devinder Gill, MD

Blood (2008) 112 (11): 4014.

https://doi.org/10.1182/blood.V112.11.4014.4014

Published: 2008

Journal Articles

Identification of Two Novel Chemokines (CCL2 and CXCL2) in B-Chronic Lymphocytic Leukaemia (B-CLL) and Prolonged Survival of Primary B-CLL Cells in Vitro

Devinder Gill, MB, FRCPath, FRACP, FRCPA, Melinda Burgess, Louise Knop, BSc, Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Nigel McMillan, PhD

Blood (2008) 112 (11): 3157.

https://doi.org/10.1182/blood.V112.11.3157.3157

Published: 2008

Journal Articles

JAK2 V617F Mutation Status Predicts Thrombotic Complications, Including Arterial Thrombosis, in Patients with Essential Thrombocytosis (ET).

Helen Weston, MBBS, Robert Bird, MBBS, Vanessa Griffiths, BSc, Mark Jones, BSc, PhD, Karen Grimmett, BSc, Russell Saal, BSc, Anthony K. Mills, MBBS, Devinder Gill, MBBS, Paula Marlton, MBBS, Peter Mollee, MBBS

Blood (2007) 110 (11): 2551.

https://doi.org/10.1182/blood.V110.11.2551.2551

Published: 2007

Journal Articles

Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant Patients.

Peter Mollee, MBBS, Matthew Hourigan, MBBS, David Johnson, MBBS, Mark Jones, BSc, Nikki Isbel, MBBS, Carmel Hawley, MBBS, Paula Marlton, MBBS, Maher Gandhi, MBBS, Scott Campbell, MBBS, Devinder Gill, MBBS

Blood (2007) 110 (11): 1366.

https://doi.org/10.1182/blood.V110.11.1366.1366

Published: 2007

Journal Articles

Prolonged Hematologic Toxicity from the Hyper-CVAD Regimen; Manifestations, Frequency, and Natural History in a Cohort of 125 Consecutive Patients.

Saar Gill, MBBS, Steven Lane, MBBS, Julie Crawford, MBBS, Peter Mollee, MBBS, Paula Marlton, MBBS, Gavin Cull, MBBS, Miles Prince, MBBS, MD, John Francis Seymour, MBBS, PhD

Blood (2006) 108 (11): 2441.

https://doi.org/10.1182/blood.V108.11.2441.2441

Published: 2006

NARROW

Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis

Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose Dexamethasone

High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Clinical Relevance of Partial Response in the Marrow (PRm) after Failure of Frontline Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML)

Emergence of Fc-Gamma-Riib-Dominance Contributes to Resistance to Therapeutic Antibodies in Patients with Chronic Lymphocytic Leukaemia

Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients

Diagnosis of Amyloidosis Subtype By Laser-Capture Microdissection (LCM) and Tandem Mass Spectrometry (MS/MS) Proteomic Analysis

Clinical Comparison of the Freelite and N-Latex Serum Free Light Chain (FLC) Assays in the Diagnosis and Monitoring of AL Amyloidosis

A Phase II Study of Risk-Adapted Intravenous Melphalan in Patients with AL Amyloidosis,

Sequential Treatment with Rituximab Followed by CHOP Chemotherapy in Adult B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) - Establishing a New Standard of Care: Final Results From the Prospective International Multicenter PTLD-1 Trial

Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6

ZAP-70 Expression Measured by Quantitative PCR (QPCR) As a Prognostic Marker in Chronic Lymphocytic Leukaemia (CLL)

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study

WT1 Expression Levels at Diagnosis and as a Marker of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukaemia (AML).

Treatment of Acute Promyelocytic Leukaemia in Jehovah’s Witness(JW) Population

Identification of Two Novel Chemokines (CCL2 and CXCL2) in B-Chronic Lymphocytic Leukaemia (B-CLL) and Prolonged Survival of Primary B-CLL Cells in Vitro

JAK2 V617F Mutation Status Predicts Thrombotic Complications, Including Arterial Thrombosis, in Patients with Essential Thrombocytosis (ET).

Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant Patients.

Prolonged Hematologic Toxicity from the Hyper-CVAD Regimen; Manifestations, Frequency, and Natural History in a Cohort of 125 Consecutive Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only